Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients 18 - 85 years of age.~2. Signed and dated informed consent document.~3. Major abscess, surgical site infection, traumatic wound infection or cellulitis suspected or confirmed to be caused by Gram-positive bacteria.~4. At least two (2) local signs and symptoms of ABSSSI and at least one (1) systemic sign of infection.~5. Requires a minimum of 3 days of IV therapy.~6. Patient willing and able to comply with study procedures.~Exclusion Criteria:~Patients presenting with any of the following:~1. A contra-indication to any required study drug.~2. Pregnant or nursing females.~3. Sustained shock.~4. Participation in another study of an investigational drug or device within 30 days.~5. Receipt of a systemically or topically administered antibiotic within 14 days prior to randomization, except receipt of a single dose of a short-acting antibacterial drug 3 or more days prior to randomization.~6. Infection due to a dalbavancin or vancomycin-resistant organism.~7. Evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic arthritis, osteomyelitis, and/or endovascular infection.~8. Exclusively gram-negative bacterial or a fungal ABSSSI.~9. Venous catheter infection.~10. Infection of a diabetic foot ulcer or a decubitus ulcer.~11. Device-related infections.~12. Gram-negative bacteremia.~13. Infected burns.~14. Infected limb with critical ischemia.~15. Superficial/simple skin and skin structure infections.~16. Concomitant condition requiring non-study antibacterial therapy.~17. ABSSSI requiring therapy for longer than 14 days.~18. Adjunctive therapy with hyperbaric oxygen.~19. More than 2 surgical interventions for ABSSSI anticipated.~20. Chronic inflammatory condition precluding assessment of clinical response.~21. Absolute neutrophil count \< 500 cells/mm3.~22. Human immunodeficiency virus (HIV) infection with a CD4 cell count \< 200 cells/mm3.~23. Recent bone marrow transplant, \> 20 mg prednisolone per day (or equivalent) or receiving immunosuppressant drugs after organ transplantation.~24. Regular, chronic antipyretic use in patients unable to modify during the first three days of study drug therapy.~25. Life expectancy less than 3 months.~26. Conditions that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results.~27. Prior participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Vancomycin with possible switch to oral linezolid (Type: ACTIVE_COMPARATOR): None
- Dalbavancin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).